Arca
Skip to content
Tools
Tools

Kidney disease

Drug research and approvals for kidney disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 1,862 studies of kidney disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 85 drug trials for it since 2013, FDA has 2 approved and 22 open orphan designations naming it, and the EU has 10 authorised medicines for it.

  • Recruiting worldwide: 1,862
  • Trials authorized in Canada: 85
  • FDA orphan approvals: 2
  • EU medicines: 10

Recruiting now

Newest posted first, of 1,862 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 4

Phase 3 12 of 26

Phase 2 12 of 35

Phase 1 or earlier 12 of 171

  • SirolimusFK506-binding protein 1A inhibitor
  • TrimethoprimBacterial dihydrofolate reductase inhibitor
  • CefepimeBacterial penicillin-binding protein inhibitor
  • AlemtuzumabCAMPATH-1 antigen inhibitor
  • CidofovirHuman herpesvirus 1 DNA polymerase inhibitor
  • CisplatinDNA inhibitor
  • GanciclovirHuman herpesvirus 1 DNA polymerase inhibitor
  • HydrocodoneOpioid receptors; mu/kappa/delta agonist
  • PropranololBeta-1 adrenergic receptor antagonist
  • QuinineFerriprotoporphyrin IX inhibitor
  • RitonavirHuman immunodeficiency virus type 1 protease inhibitor
  • SunitinibMacrophage colony stimulating factor receptor inhibitor

How its trials ended

4,311 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 910 whose ending is known, 45% met their primary endpoint, 10% missed it and 45% stopped early.

  • Completed, result not reported1,83543%
  • Ongoing91721%
  • Status unknown64915%
  • Met its primary endpoint4059%
  • Stopped: other or unclear2345%
  • Missed its primary endpoint952%
  • Stopped: enrollment or feasibility792%
  • Stopped: sponsor or business decision501%
  • Stopped: lack of efficacy21<1%
  • Stopped: funding21<1%
  • Stopped: safety5<1%

Trials authorized in Canada

The 10 newest of 85; search them all in Canada trials
Nov 13, 2026A phase 1, randomized, double-blinded, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and…EPRA-0322Epok Therapeutics Inc.Pending
Jul 30, 2026A phase III, randomised, double-blind, study to evaluate the effect of balcinrenone/dapagliflozin compared with dapagliflozin on renal and cardiovascular…Balcinrenone-dapagliflozin (AZD2961) / DapagliflozinAstraZeneca PharmaceuticalsOngoing
May 12, 2026A phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the effect of elecoglipron in reducing renal outcomes…Elecoglipron (AZD5004) / DapagliflozinAstraZeneca PharmaceuticalsOngoing
Dec 16, 2025Podomount-basket, a phase II, multicentre, randomised, 2-arm parallel-group, double-blind, placebo-controlled basket trial to assess safety, tolerability, pk,…BI 764198Boehringer Ingelheim (Canada) Ltd LteeOngoing
Nov 12, 2025A phase IIb, randomised, multicentre, double-blind study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat on…Baxdrostat / DapagliflozinAstraZeneca PharmaceuticalsOngoing
Sep 22, 2025A phase 3, randomized, double-blind, placebo-controlled, event-driven study to investigate the effect of orforglipron on the incidence of major adverse…Orforglipron (LY3502970)Eli LillyOngoing
Aug 28, 2025A phase 2a, open-label, single-arm study to evaluate the efficacy, safety, and pharmacokinetics of VX-407 in subjects with autosomal dominant polycystic kidney…VX-407Vertex PharmaceuticalsOngoing
Jul 30, 2025A randomised, double-blind, placebo-controlled trial with an open-label extension to assess the pharmacokinetics, safety, and efficacy of empagliflozin tablets…EmpagliflozinBoehringer Ingelheim (Canada) Ltd LteeOngoing
Mar 27, 2025A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABBV-CLS-628 in adult subjects with autosomal…ABBV-CLS-628Calico Life Sciences LLCOngoing
Mar 19, 2025A randomised, double blind, placebo-controlled, single ascending dose, phase 1a/1b multi-centre study in healthy participants and participants with autosomal…GSK4771261GSKOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 24
Apr 23, 2018JynarqueJYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease…Otsuka Pharmaceutical Company, Ltd.Approved
Oct 18, 2016ZemplarIndicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism…Abbvie, inc.Approved
Aug 19, 2026Eukaryotic ribosome-selective glycosideTreatment of autosomal dominant polycystic kidney diseaseEloxx PharmaceuticalsDesignated
Jul 8, 2026Human IgG1kappa monoclonal antibody that specifically binds…Treatment of autosomal dominant polycystic kidney diseaseAstraZeneca Pharmaceuticals LPDesignated
Mar 26, 2026TamibaroteneTreatment of autosomal dominant polycystic kidney diseaseRege Nephro Co., Ltd.Designated
Nov 1, 2025Fully human IgG1 monoclonal antibody that binds to human…Treatment of autosomal dominant polycystic kidney diseaseCalico Life Sciences LLCDesignated
Sep 8, 2025OctreotideTreatment of autosomal dominant polycystic kidney diseaseCamurus ABDesignated
Sep 5, 2025SalsalateTreatment of autosomal dominant polycystic kidney diseaseJ & D Pharmaceuticals LLCDesignated
Aug 29, 2025Anti-PAPPA mAbTreatment of autosomal dominant polycystic kidney disease (ADPKD)GlaxoSmithKline Research & Development LimitedDesignated
Feb 12, 2024(S)-2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy-1…Treatment of autosomal dominant polycystic kidney disease (ADPKD)Shanghai Alebund Pharmaceuticals Ltd.Designated
Apr 20, 2023OxypurinolTreatment of autosomal dominant polycystic kidney diseaseXORTX Therapeutics Inc.Designated
Nov 22, 2022MebendazoleTreatment of Autosomal Dominant Polycystic Kidney DiseaseHealx Technology LimitedDesignated
Sep 14, 2022Potassium…Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)SCYNEXIS, Inc.Designated
Jun 16, 2022A chemically modified full phosphorothioate-backbone…Autosomal dominant polycystic kidney disease (ADPKD)Novartis Pharmaceuticals CorporationDesignated
May 26, 2021TesevatinibTreatment of autosomal dominant polycystic kidney diseaseKadmon CorporationDesignated

Medicines authorised in the EU

Newest first
May 29, 2026BopediatFurosemideProveca Pharma LimitedEMA ↗
Jun 11, 2025XoanacylFerric citrate coordination complexAveroaEMA ↗
Apr 24, 2023VafseoVadadustatMedice Arzneimittel Pütter GmbH & Co. KGEMA ↗
Apr 25, 2022KapruviaDifelikefalinVifor Fresenius Medical Care Renal Pharma FranceEMA ↗
Feb 16, 2022KerendiaFinerenoneBayer AGEMA ↗
Aug 18, 2021EvrenzoRoxadustatAstellas Pharma Europe B.V.EMA ↗
Nov 11, 2016ParsabivEtelcalcetideAmgen Europe B.V.EMA ↗
May 27, 2015JinarcTolvaptanOtsuka Pharmaceutical Netherlands B.V.EMA ↗
Aug 26, 2014VelphoroSucroferric oxyhydroxideVifor Fresenius Medical Care Renal Pharma FranceEMA ↗
Jul 20, 2007MirceraMethoxy polyethylene glycol-epoetin betaRoche Registration GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.